VAN HOUTE HANS (Chief Financial Officer) sold 27.2% of their position (14.05K shares) of NURIX THERAPEUTICS, INC. on the open market
Open‑market sale worth $233.3K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 5/5/2026ACC: 0001817217-26-000008
Officer· Chief Financial Officer
Since Jul 2020
-14.05K
Net shares
Net seller
$233.3K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
14.05K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−13.47K
Price / share
$16.58
Trade value
$223.32K
% of position
26.1%
5/5/2026
51.65K→38.17K
Common Stock
Direct
Shares
−582.00
Price / share
$17.18
Trade value
$10K
% of position
1.5%
5/5/2026
38.17K→37.59K
Total
Net shares
−14.05K
Net value
-$233.32K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/5/2026 | S · Sale | −13.47K | $16.58 | $223.32K | 26.1% | 51.65K | 38.17K |
| Common Stock Direct | 5/5/2026 | S · Sale | −582.00 | $17.18 | $10K | 1.5% | 38.17K | 37.59K |
| Total | −14.05K | -$233.32K | ||||||
Derivative Transactions0
No derivative transactions reported